Format

Send to

Choose Destination
Oncotarget. 2017 Oct 11;8(63):106721-106739. doi: 10.18632/oncotarget.21828. eCollection 2017 Dec 5.

Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models.

Author information

1
Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute, Suwon 440-746, Republic of Korea.
2
National Development Institute of Korean Medicine, Gyeongsan 38540, Republic of Korea.
3
College of Pharmacy, Chosun University, Gwangju 501-759, Republic of Korea.
4
Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
5
Department of Pathology, Division of Neuropathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
6
Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon, Gyeonggi-Do 440-746, Republic of Korea.
7
Well Aging Research Center, Daegu Geongbuk Institute of Science and Technology, Daegu 42988, South Korea.
8
Companion Diagnostics and Medical Technology Research Group, Daegu Geongbuk Institute of Science and Technology, Daegu 42988, South Korea.

Abstract

RNF146 is an E3 ubiquitin ligase that specifically recognizes and polyubiquitinates poly (ADP-ribose) (PAR)-conjugated substrates for proteasomal degradation. RNF146 has been shown to be neuroprotective against PAR polymerase-1 (PARP1)-induced cell death during stroke. Here we report that RNF146 expression and RNF146 inducers can prevent cell death elicited by Parkinson's disease (PD)-associated and PARP1-activating stimuli. In SH-SY5Y cells, RNF146 expression conferred resistance to toxic stimuli that lead to PARP1 activation. High-throughput screen using a luciferase construct harboring the RNF146 promoter identified liquiritigenin as an RNF146 inducer. We found that RNF146 expression by liquiritigenin was mediated by estrogen receptor activation and contributed to cytoprotective effect of liquiritigenin. Finally, RNF146 expression by liquiritigenin in mouse brains provided dopaminergic neuroprotection in a 6-hydroxydopamine PD mouse model. Given the presence of PARP1 activity and RNF146 deficits in PD, it could be a potential therapeutic strategy to restore RNF146 expression by natural compounds or estrogen receptor activation.

KEYWORDS:

AIMP2; PARP1-dependent cell death; RNF146; luciferase screen; preconditioning

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center